In the past week, ALXO stock has gone up by 10.40%, with a monthly gain of 13.75% and a quarterly surge of 6.51%. The volatility ratio for the week is 11.02%, and the volatility levels for the last 30 days are 8.29% for Alx Oncology Holdings Inc The simple moving average for the last 20 days is 13.40% for ALXO stock, with a simple moving average of 44.07% for the last 200 days.
Is It Worth Investing in Alx Oncology Holdings Inc (NASDAQ: ALXO) Right Now?
The stock has a 36-month beta value of 1.30. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ALXO is 27.39M, and at present, short sellers hold a 11.39% of that float. On April 23, 2024, the average trading volume of ALXO was 459.33K shares.
ALXO) stock’s latest price update
Alx Oncology Holdings Inc (NASDAQ: ALXO)’s stock price has decreased by -8.78 compared to its previous closing price of 15.60. However, the company has seen a 10.40% increase in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-11 that ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.
Analysts’ Opinion of ALXO
Many brokerage firms have already submitted their reports for ALXO stocks, with Stifel repeating the rating for ALXO by listing it as a “Hold.” The predicted price for ALXO in the upcoming period, according to Stifel is $14 based on the research report published on March 08, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see ALXO reach a price target of $18, previously predicting the price at $8. The rating they have provided for ALXO stocks is “Buy” according to the report published on December 08th, 2023.
Jefferies gave a rating of “Hold” to ALXO, setting the target price at $25 in the report published on December 22nd of the previous year.
ALXO Trading at 4.61% from the 50-Day Moving Average
After a stumble in the market that brought ALXO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.31% of loss for the given period.
Volatility was left at 8.29%, however, over the last 30 days, the volatility rate increased by 11.02%, as shares surge +21.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.97% upper at present.
During the last 5 trading sessions, ALXO rose by +10.40%, which changed the moving average for the period of 200-days by +124.80% in comparison to the 20-day moving average, which settled at $12.67. In addition, Alx Oncology Holdings Inc saw -4.43% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALXO starting from Pons Jaume, who sale 50,000 shares at the price of $14.20 back on Apr 16 ’24. After this action, Pons Jaume now owns 604,205 shares of Alx Oncology Holdings Inc, valued at $710,195 using the latest closing price.
Pons Jaume, the PRESIDENT & CSO of Alx Oncology Holdings Inc, sale 20,000 shares at $11.15 during a trade that took place back on Apr 04 ’24, which means that Pons Jaume is holding 628,359 shares at $223,036 based on the most recent closing price.
Stock Fundamentals for ALXO
The total capital return value is set at -0.82. Equity return is now at value -70.97, with -58.58 for asset returns.
Based on Alx Oncology Holdings Inc (ALXO), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -11.63. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -217.47.
Currently, EBITDA for the company is -169.44 million with net debt to EBITDA at 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.24.
Conclusion
To sum up, Alx Oncology Holdings Inc (ALXO) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
